Review: Is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?

Arthritis and Rheumatology

Volumn 66, Issue 6, 2014, Pages 1405-1413

  Nigrovic, Peter A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CANAKINUMAB; CORTICOSTEROID; CRYOPYRIN; D DIMER; FC RECEPTOR; FERRITIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6; PROTEIN KINASE ZAP 70; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; TOCILIZUMAB;

BODY TEMPERATURE; CHRONIC ARTHRITIS; CLINICAL FEATURE; CORTICOSTEROID THERAPY; CYTOKINE STORM; DISEASE PREDISPOSITION; DISSEMINATED INTRAVASCULAR CLOTTING; ERYTHEMA; ERYTHROCYTE SEDIMENTATION RATE; FERRITIN BLOOD LEVEL; FEVER; GENE DELETION; GENETIC LINKAGE; HEPATITIS; HUMAN; HYPERFERRITINEMIA; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; JUVENILE RHEUMATOID ARTHRITIS; MACROPHAGE ACTIVATION SYNDROME; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RASH; REMISSION; REVIEW; SEPSIS; SYSTEMIC DISEASE; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS; TH17 CELL;

ADOLESCENT; ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; CHILD; CHILD, PRESCHOOL; CYTOKINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; MICE; TREATMENT OUTCOME;

EID: 84901606673     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38615     Document Type: Review

References (85)

1. Ogilvie EM, Fife MS, Thompson SD, Twine N, Tsoras M, Moroldo M, et al. The -174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: a multicenter study using simplex and multiplex juvenile idiopathic arthritis families. Arthritis Rheum 2003; 48: 3202-6.
2. Behrens EM, Beukelman T, Gallo L, Spangler J, Rosenkranz M, Arkachaisri T, et al. Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). J Rheumatol 2008; 35: 343-8.
3. Russo RA, Katsicas MM,. Patients with very early-onset systemic juvenile idiopathic arthritis exhibit more inflammatory features and a worse outcome. J Rheumatol 2013; 40: 329-34.
4. Canna SW, Behrens EM,. Making sense of the cytokine storm: a conceptual framework for understanding, diagnosing, and treating hemophagocytic syndromes. Pediatr Clin North Am 2012; 59: 329-44.
5. Lomater C, Gerloni V, Gattinara M, Mazzotti J, Cimaz R, Fantini F,. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol 2000; 27: 491-6.
6. Fantini F, Gerloni V, Gattinara M, Cimaz R, Arnoldi C, Lupi E,. Remission in juvenile chronic arthritis: a cohort study of 683 consecutive cases with a mean 10 year followup. J Rheumatol 2003; 30: 579-84.
7. Spiegel LR, Schneider R, Lang BA, Birdi N, Silverman ED, Laxer RM, et al. Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum 2000; 43: 2402-9.
8. Singh-Grewal D, Schneider R, Bayer N, Feldman BM,. Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum 2006; 54: 1595-601.
9. Nigrovic PA, White PH,. Care of the adult with juvenile rheumatoid arthritis. Arthritis Rheum 2006; 55: 208-16.
10. Polito C, Strano CG, Olivieri AN, Alessio M, Iammarrone CS, Todisco N, et al. Growth retardation in non-steroid treated juvenile rheumatoid arthritis. Scand J Rheumatol 1997; 26: 99-103.
11. Minden K,. Adult outcomes of patients with juvenile idiopathic arthritis. Horm Res 2009; 72 Suppl 1: 20-5.
12. Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011; 63: 545-55.
13. Oen K, Duffy CM, Tse SM, Ramsey S, Ellsworth J, Chedeville G, et al. Early outcomes and improvement of patients with juvenile idiopathic arthritis enrolled in a Canadian multicenter inception cohort. Arthritis Care Res (Hoboken) 2010; 62: 527-36.
14. Schneider R, Lang BA, Reilly BJ, Laxer RM, Silverman ED, Ibanez D, et al. Prognostic indicators of joint destruction in systemic-onset juvenile rheumatoid arthritis. J Pediatr 1992; 120: 200-5.
15. Sandborg C, Holmes TH, Lee T, Biederman K, Bloch DA, Emery H, et al. Candidate early predictors for progression to joint damage in systemic juvenile idiopathic arthritis. J Rheumatol 2006; 33: 2322-9.
16. Russo RA, Katsicas MM,. Global damage in systemic juvenile idiopathic arthritis: preliminary early predictors. J Rheumatol 2008; 35: 1151-6.
17. Bloom BJ, Alario AJ, Miller LC,. Persistent elevation of fibrin D-dimer predicts longterm outcome in systemic juvenile idiopathic arthritis. J Rheumatol 2009; 36: 422-6.
18. Verbsky JW, White AJ,. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 2004; 31: 2071-5.
19. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J,. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201: 1479-86.
20. Gattorno M, Piccini A, Lasiglie D, Tassi S, Brisca G, Carta S, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2008; 58: 1505-15.
21. Lequerre T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008; 67: 302-8.
22. Zeft A, Hollister R, LaFleur B, Sampath P, Soep J, McNally B, et al. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. J Clin Rheumatol 2009; 15: 161-4.
23. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A,. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202-9.
24. Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011; 70: 747-54.
25. Lovell DJ, Giannini EH, Reiff AO, Kimura Y, Li S, Hashkes PJ, et al. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum 2013; 65: 2486-96.
26. Ilowite NT, Prather K, Lokhnygina Y, Schanberg LE, Elder M, Milojevic D, et al. The randomized placebo phase study of rilonacept in the treatment of systemic juvenile idiopathic arthritis [abstract]. Arthritis Rheum 2013; 65 Suppl: S757-8.
27. Ruperto N, Quartier P, Wulffraat N, Woo P, Ravelli A, Mouy R, et al, for the Paediatric Rheumatology International Clinical Trials Organisation. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum 2012; 64: 557-67.
28. Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367: 2396-406.
29. Al-Homood IA,. Biologic treatments for adult-onset Still's disease. Rheumatology (Oxford) 2014; 53: 32-8.
30. Hedrich CM, Bruck N, Fiebig B, Gahr M,. Anakinra: a safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA). Rheumatol Int 2012; 32: 3525-30.
31. Vastert SJ, de Jager W, Noordman BJ, Holzinger D, Kuis W, Prakken BJ, et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol 2014; 66: 1034-43.
32. Quartier P, Brunner H, Constantin T, Padeh S, Calvo I, Erguven M, et al, and PRINTO/PRCSG. Efficacy of canakinumab in the treatment of systemic juvenile idiopathic arthritis: a 12-week pooled post-hoc analysis [abstract]. Pediatr Rheumatol 2013; 11 Suppl 2: P169.
33. Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. N Engl J Med 2006; 355: 581-92.
34. Sibley CH, Plass N, Snow J, Wiggs EA, Brewer CC, King KA, et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum 2012; 64: 2375-86.
35. Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009; 360: 2426-37.
36. Ilowite N, Porras O, Reiff A, Rudge S, Punaro M, Martin A, et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 2009; 28: 129-37.
37. Urien S, Bardin C, Bader-Meunier B, Mouy R, Compeyrot-Lacassagne S, Foissac F, et al. Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes. BMC Pharmacol Toxicol 2013; 14: 40.
38. DeWitt EM, Kimura Y, Beukelman T, Nigrovic PA, Onel K, Prahalad S, et al, on behalf of the Juvenile Idiopathic Arthritis Disease-Specific Research Committee of the Childhood Arthritis and Rheumatology Research Alliance. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2012; 64: 1001-10.
39. Ringold S, Weiss PF, Beukelman T, DeWitt EM, Ilowite NT, Kimura Y, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum 2013; 65: 2499-512.
40. Mellins ED, Macaubas C, Grom AA,. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol 2011; 7: 416-26.
41. De Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A,. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991; 34: 1158-63.
42. Ogilvie EM, Khan A, Hubank M, Kellam P, Woo P,. Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheum 2007; 56: 1954-65.
43. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008; 371: 998-1006.
44. De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367: 2385-95.
45. Sakai R, Nagasawa H, Nishi E, Okuyama A, Takei H, Kurasawa T, et al. Successful treatment of adult-onset Still's disease with tocilizumab monotherapy: two case reports and literature review. Clin Rheumatol 2012; 31: 569-74.
46. Gabay C, Lamacchia C, Palmer G,. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 2010; 6: 232-41.
47. Dinarello CA,. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011; 117: 3720-32.
48. Joosten LA,. Excessive interleukin-1 signaling determines the development of Th1 and Th17 responses in chronic inflammation [editorial]. Arthritis Rheum 2010; 62: 320-2.
49. Kleinewietfeld M, Hafler DA,. The plasticity of human Treg and Th17 cells and its role in autoimmunity. Semin Immunol 2013; 25: 305-12.
50. H17 cells produce IFN-γ or IL-10 and are regulated by IL-1β. Nature 2012; 484: 514-8.
51. Ferraccioli G, Bracci-Laudiero L, Alivernini S, Gremese E, Tolusso B, De Benedetti F,. Interleukin-1β and interleukin-6 in arthritis animal models: roles in the early phase of transition from acute to chronic inflammation and relevance for human rheumatoid arthritis. Mol Med 2010; 16: 552-7.
52. Monach PA, Benoist C, Mathis D,. The role of antibodies in mouse models of rheumatoid arthritis, and relevance to human disease. Adv Immunol 2004; 82: 217-48.
53. Sakaguchi N, Takahashi T, Hata H, Nomura T, Tagami T, Yamazaki S, et al. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 2003; 426: 454-60.
54. Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000; 191: 313-20.
55. Kagari T, Doi H, Shimozato T,. The importance of IL-1β and TNF-α, and the noninvolvement of IL-6, in the development of monoclonal antibody-induced arthritis. J Immunol 2002; 169: 1459-66.
56. Ji H, Pettit A, Ohmura K, Ortiz-Lopez A, Duchatelle V, Degott C, et al. Critical roles for interleukin 1 and tumor necrosis factor α in antibody-induced arthritis. J Exp Med 2002; 196: 77-85.
57. Nigrovic PA, Binstadt BA, Monach PA, Johnsen A, Gurish M, Iwakura Y, et al. Mast cells contribute to initiation of autoantibody-mediated arthritis via IL-1. Proc Natl Acad Sci U S A 2007; 104: 2325-30.
58. Luross JA, Williams NA,. The genetic and immunopathological processes underlying collagen-induced arthritis. Immunology 2001; 103: 407-16.
59. Joosten LA, Helsen MM, van de Loo FA, van den Berg WB,. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNF α, anti-IL-1α/β, and IL-1Ra. Arthritis Rheum 1996; 39: 797-809.
60. Saijo S, Asano M, Horai R, Yamamoto H, Iwakura Y,. Suppression of autoimmune arthritis in interleukin-1-deficient mice in which T cell activation is impaired due to low levels of CD40 ligand and OX40 expression on T cells. Arthritis Rheum 2002; 46: 533-44.
61. Hata H, Sakaguchi N, Yoshitomi H, Iwakura Y, Sekikawa K, Azuma Y, et al. Distinct contribution of IL-6, TNF-α, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J Clin Invest 2004; 114: 582-8.
62. + Th cells that cause autoimmune arthritis. J Exp Med 2007; 204: 41-7.
63. Horai R, Nakajima A, Habiro K, Kotani M, Nakae S, Matsuki T, et al. TNF-α is crucial for the development of autoimmune arthritis in IL-1 receptor antagonist-deficient mice. J Clin Invest 2004; 114: 1603-11.
64. Kotani M, Hirata K, Ogawa S, Habiro K, Ishida Y, Tanuma S, et al. CD28-dependent differentiation into the effector/memory phenotype is essential for induction of arthritis in interleukin-1 receptor antagonist-deficient mice. Arthritis Rheum 2006; 54: 473-81.
65. Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y,. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci U S A 2003; 100: 5986-90.
66. Koenders MI, Devesa I, Marijnissen RJ, Abdollahi-Roodsaz S, Boots AM, Walgreen B, et al. Interleukin-1 drives pathogenic Th17 cells during spontaneous arthritis in interleukin-1 receptor antagonist-deficient mice. Arthritis Rheum 2008; 58: 3461-70.
67. + immune regulatory network. Blood 2006; 107: 1696-702.
68. H17 cells: lesson from NLPR3 mutated patients. PLoS One 2011; 6: e20014.
69. Omoyinmi E, Hamaoui R, Pesenacker A, Nistala K, Moncrieffe H, Ursu S, et al. Th1 and Th17 cell subpopulations are enriched in the peripheral blood of patients with systemic juvenile idiopathic arthritis. Rheumatology (Oxford) 2012; 51: 1881-6.
70. Date Y, Seki N, Kamizono S, Higuchi T, Hirata T, Miyata K, et al. Identification of a genetic risk factor for systemic juvenile rheumatoid arthritis in the 5-flanking region of the TNFα gene and HLA genes. Arthritis Rheum 1999; 42: 2577-82.
71. Thomson W, Barrett JH, Donn R, Pepper L, Kennedy LJ, Ollier WE, et al. Juvenile idiopathic arthritis classified by the ILAR criteria: HLA associations in UK patients. Rheumatology (Oxford) 2002; 41: 1183-9.
72. Ombrello MJ, Remmers EF, Tachmazidou I, Grom AA, Foll D, Martini A, et al. Genome wide association meta-analysis implicates HLA-DRB1, the BTNL2/HLA-DRA region, and a novel susceptibility locus on chromosome 1 in systemic juvenile idiopathic arthritis [abstract]. Arthritis Rheum 2013; 65 Suppl: S937.
73. Record JL, Beukelman T, Cron RQ,. Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series. J Rheumatol 2011; 38: 180-1.
74. Shimizu M, Nakagishi Y, Yachie A,. Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles. Cytokine 2013; 61: 345-8.
75. Ovadia A, Livneh A, Feld O, Ben-Zvi I, Kukuy E, Kivity S, et al. T helper 17 polarization in familial Mediterranean fever. Genes Immun 2013; 14: 212-6.
76. Srivastava S, Macaubas C, Deshpande C, Alexander HC, Chang SY, Sun Y, et al. Monocytes are resistant to apoptosis in systemic juvenile idiopathic arthritis. Clin Immunol 2010; 136: 257-68.
77. Macaubas C, Nguyen KD, Peck A, Buckingham J, Deshpande C, Wong E, et al. Alternative activation in systemic juvenile idiopathic arthritis monocytes. Clin Immunol 2012; 142: 362-72.
78. Grom AA, Villanueva J, Lee S, Goldmuntz EA, Passo MH, Filipovich A,. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr 2003; 142: 292-6.
79. Wulffraat NM, Rijkers GT, Elst E, Brooimans R, Kuis W,. Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation. Rheumatology (Oxford) 2003; 42: 375-9.
80. Hazen MM, Woodward AL, Hofmann I, Degar BA, Grom A, Filipovich AH, et al. Mutations of the hemophagocytic lymphohistiocytosis-associated gene UNC13D in a patient with systemic juvenile idiopathic arthritis. Arthritis Rheum 2008; 58: 567-70.
81. Vastert SJ, van Wijk R, D'Urbano LE, de Vooght KM, de Jager W, Ravelli A, et al. Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford) 2010; 49: 441-9.
82. Villanueva J, Lee S, Giannini EH, Graham TB, Passo MH, Filipovich A, et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther 2005; 7: R30-7.
83. Kimura Y, Weiss JE, Haroldson KL, Lee T, Punaro M, Oliveira S, et al, and the Childhood Arthritis and Rheumatology Research Alliance CARRA net Investigators. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2013; 65: 745-52.
84. Beukelman T, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG, et al, on behalf of the SABER Collaboration. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012; 64: 2773-80.
85. Fisher CJ Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. JAMA 1994; 271: 1836-43.